Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 13 de 13
Filter
Add more filters










Publication year range
1.
Am J Pathol ; 186(11): 2957-2969, 2016 11.
Article in English | MEDLINE | ID: mdl-27640146

ABSTRACT

Plasmodium berghei ANKA infection of C57BL/6 mice is a widely used model of experimental cerebral malaria (ECM). By contrast, the nonneurotropic P. berghei NK65 (PbN) causes severe malarial disease in C57BL/6 mice but does not cause ECM. Previous studies suggest that endothelin-1 (ET-1) contributes to the pathogenesis of ECM. In this study, we characterize the role of ET-1 on ECM vascular dysfunction. Mice infected with 106 PbN-parasitized red blood cells were treated with either ET-1 or saline from 2 to 8 days postinfection (dpi). Plasmodium berghei ANKA-infected mice served as the positive control. ET-1-treated PbN-infected mice exhibited neurological signs, hypothermia, and behavioral alterations characteristic of ECM, dying 4 to 8 dpi. Parasitemia was not affected by ET-1 treatment. Saline-treated PbN-infected mice did not display ECM, surviving until 12 dpi. ET-1-treated PbN-infected mice displayed leukocyte adhesion to the vascular endothelia and petechial hemorrhages throughout the brain at 6 dpi. Intravital microscopic images demonstrated significant brain arteriolar vessel constriction, decreased functional capillary density, and increased blood-brain barrier permeability. These alterations were not present in either ET-1-treated uninfected or saline-treated PbN-infected mice. In summary, ET-1 treatment of PbN-infected mice induced an ECM-like syndrome, causing brain vasoconstriction, adherence of activated leukocytes in the cerebral microvasculature, and blood-brain barrier leakage, indicating that ET-1 is involved in the genesis of brain microvascular alterations that are the hallmark of ECM.


Subject(s)
Endothelin-1/adverse effects , Malaria, Cerebral/pathology , Plasmodium berghei/physiology , Animals , Blood-Brain Barrier/drug effects , Brain/pathology , Cell Adhesion , Disease Models, Animal , Endothelin-1/therapeutic use , Endothelium, Vascular/pathology , Female , Leukocytes/pathology , Malaria, Cerebral/drug therapy , Mice , Mice, Inbred C57BL , Parasitemia
2.
PLoS Pathog ; 12(3): e1005477, 2016 Mar.
Article in English | MEDLINE | ID: mdl-27031954

ABSTRACT

Plasmodium falciparum infection causes a wide spectrum of diseases, including cerebral malaria, a potentially life-threatening encephalopathy. Vasculopathy is thought to contribute to cerebral malaria pathogenesis. The vasoactive compound endothelin-1, a key participant in many inflammatory processes, likely mediates vascular and cognitive dysfunctions in cerebral malaria. We previously demonstrated that C57BL6 mice infected with P. berghei ANKA, our fatal experimental cerebral malaria model, sustained memory loss. Herein, we demonstrate that an endothelin type A receptor (ETA) antagonist prevented experimental cerebral malaria-induced neurocognitive impairments and improved survival. ETA antagonism prevented blood-brain barrier disruption and cerebral vasoconstriction during experimental cerebral malaria, and reduced brain endothelial activation, diminishing brain microvascular congestion. Furthermore, exogenous endothelin-1 administration to P. berghei NK65-infected mice, a model generally regarded as a non-cerebral malaria negative control for P. berghei ANKA infection, led to experimental cerebral malaria-like memory deficits. Our data indicate that endothelin-1 is critical in the development of cerebrovascular and cognitive impairments with experimental cerebral malaria. This vasoactive peptide may thus serve as a potential target for adjunctive therapy in the management of cerebral malaria.


Subject(s)
Blood-Brain Barrier/metabolism , Brain/blood supply , Cognition Disorders/metabolism , Endothelin-1/metabolism , Malaria, Cerebral/pathology , Animals , Brain/metabolism , Brain/pathology , Cognition Disorders/pathology , Disease Models, Animal , Mice, Inbred C57BL , Plasmodium berghei/metabolism , Time
3.
J Med Chem ; 58(19): 7895-9, 2015 Oct 08.
Article in English | MEDLINE | ID: mdl-26367273

ABSTRACT

Hybrid products in which the dihydroartemisinin scaffold is combined with NO-donor furoxan and NONOate moieties have been synthesized and studied as potential tools for the treatment of cerebral malaria (CM). The designed products were able to dilate rat aorta strips precontracted with phenylephrine with a NO-dependent mechanism. All hybrid compounds showed preserved antiplasmodial activity in vitro and in vivo against Plasmodium berghei ANKA, comparable to artesunate and artemether. Hybrid 10, selected for additional studies, was capable of increasing survival of mice with late-stage CM from 27.5% to 51.6% compared with artemether. Artemisinin-NO-donor hybrid compounds show promise as potential new drugs for treating cerebral malaria.


Subject(s)
Antimalarials/chemistry , Antimalarials/pharmacology , Artemisinins/chemistry , Malaria, Cerebral/drug therapy , Nitric Oxide Donors/chemistry , Nitric Oxide Donors/pharmacology , Animals , Antimalarials/chemical synthesis , Artemether , Artemisinins/pharmacology , Artesunate , Chemistry Techniques, Synthetic , Mice , Molecular Targeted Therapy/methods , Muscle Relaxation/drug effects , Plasmodium berghei/drug effects , Rats , Vasodilator Agents/chemistry , Vasodilator Agents/pharmacology
4.
Acta Trop ; 141(Pt A): 46-53, 2015 Jan.
Article in English | MEDLINE | ID: mdl-25312338

ABSTRACT

Over 20 species of Angiostrongylus have been described from around the world, but only Angiostrongylus cantonensis has been confirmed to cause central nervous system disease in humans. A neurotropic parasite that matures in the pulmonary arteries of rats, A. cantonensis is the most common cause of eosinophilic meningitis in southern Asia and the Pacific and Caribbean islands. The parasite can also cause encephalitis/encephalomyelitis and rarely ocular angiostrongyliasis. The present paper reviews the life cycle, epidemiology, pathogenesis, clinical features, diagnosis, treatment, prevention and prognosis of A. cantonesis infection. Emphasis is given on the spectrum of central nervous system manifestations and disease pathogenesis.


Subject(s)
Angiostrongylus cantonensis/physiology , Encephalomyelitis/epidemiology , Eosinophilia/epidemiology , Infectious Encephalitis/epidemiology , Life Cycle Stages , Meningitis/epidemiology , Strongylida Infections/epidemiology , Animals , Asia/epidemiology , Encephalomyelitis/prevention & control , Encephalomyelitis/therapy , Eosinophilia/prevention & control , Eosinophilia/therapy , Humans , Infectious Encephalitis/prevention & control , Infectious Encephalitis/therapy , Larva/physiology , Meningitis/prevention & control , Meningitis/therapy , Strongylida Infections/prevention & control , Strongylida Infections/therapy
5.
Virulence ; 4(8): 686-97, 2013 Nov 15.
Article in English | MEDLINE | ID: mdl-24128424

ABSTRACT

Ischemia and hypoxia have been implicated in cerebral malaria (CM) pathogenesis, although direct measurements of hypoxia have not been conducted. C57BL/6 mice infected with Plasmodium berghei ANKA (PbA) develop a neurological syndrome known as experimental cerebral malaria (ECM), whereas BALB/c mice are resistant to ECM. In this study, intravital microscopy methods were used to quantify hemodynamic changes, vascular/tissue oxygen (O2) tension (PO2), and perivascular pH in vivo in ECM and non-ECM models, employing a closed cranial window model. ECM mice on day 6 of infection showed marked decreases in pial blood flow, vascular (arteriolar, venular), and perivascular PO2, perivascular pH, and systemic hemoglobin levels. Changes were more dramatic in mice with late-stage ECM compared with mice with early-stage ECM. These changes led to drastic decreases in O2 delivery to the brain tissue. In addition, ECM animals required a greater PO2 gradient to extract the same amount of O2 compared with non-infected animals, as the pial tissues extract O2 from the steepest portion of the blood O2 equilibrium curve. ECM animals also showed increased leukocyte adherence in postcapillary venules, and the intensity of adhesion was inversely correlated with blood flow and O2 extraction. PbA-infected BALB/c mice displayed no neurological signs on day 6 and while they did show changes similar to those observed in C57BL/6 mice (decreased pial blood flow, vascular/tissue PO2, perivascular pH, hemoglobin levels), non-ECM animals preserved superior perfusion and oxygenation compared with ECM animals at similar anemia and parasitemia levels, resulting in better O2 delivery and O2 extraction by the brain tissue. In conclusion, direct quantitative assessment of pial hemodynamics and oxygenation in vivo revealed that ECM is associated with severe progressive brain tissue hypoxia and acidosis.


Subject(s)
Brain/pathology , Hypoxia/pathology , Malaria, Cerebral/pathology , Animals , Blood Chemical Analysis , Brain Chemistry , Disease Models, Animal , Humans , Hydrogen-Ion Concentration , Mice , Mice, Inbred BALB C , Mice, Inbred C57BL , Microscopy , Partial Pressure , Plasmodium berghei/growth & development
6.
Antimicrob Agents Chemother ; 57(11): 5462-71, 2013 Nov.
Article in English | MEDLINE | ID: mdl-23979751

ABSTRACT

Cerebral malaria (CM) is associated with low nitric oxide (NO) bioavailability, cerebrovascular constriction, occlusion, and hypoperfusion. Administration of exogenous NO partially prevents the neurological syndrome and associated vascular pathology in an experimental CM (ECM) mouse model. In this study, we evaluated the effects of transdermal glyceryl trinitrate in preventing ECM and, in combination with artemether, rescuing late-stage ECM mice from mortality. The glyceryl trinitrate and/or artemether effect on survival and clinical recovery was evaluated in C57BL/6 mice infected with P. berghei ANKA. NO synthase (NOS) expression in mouse brain was determined by Western blots. Mean arterial pressure (MAP) and pial arteriolar diameter were monitored using a tail-cuff blood pressure system and a cranial window preparation, respectively. Preventative administration of glyceryl trinitrate at 0.025 mg/h decreased ECM mortality from 67 to 11% and downregulated inducible NOS expression in the brain. When administered as adjunctive rescue therapy with artemether, glyceryl trinitrate increased survival from 47 to 79%. The adjunctive therapy caused a sustained reversal of pial arteriolar vasoconstriction in ECM mice, an effect not observed with artemether alone. Glyceryl trinitrate induced a 13% decrease in MAP in uninfected mice but did not further affect MAP in hypotensive ECM mice. Glyceryl trinitrate, when combined with artemether, was an effective adjunctive rescue treatment for ECM. This treatment ameliorated pial arteriolar vasospasm and did not significantly affect MAP. These results indicate that transdermal glyceryl trinitrate has potential to be considered as a candidate for adjunctive therapy for CM.


Subject(s)
Antimalarials/pharmacology , Artemisinins/pharmacology , Brain/drug effects , Malaria, Cerebral/drug therapy , Nitroglycerin/pharmacology , Vasodilator Agents/pharmacology , Administration, Cutaneous , Animals , Artemether , Arterial Pressure , Brain/blood supply , Brain/parasitology , Drug Synergism , Female , Gene Expression/drug effects , Malaria, Cerebral/mortality , Malaria, Cerebral/parasitology , Mice , Mice, Inbred C57BL , Nitric Oxide Synthase Type I/antagonists & inhibitors , Nitric Oxide Synthase Type I/genetics , Nitric Oxide Synthase Type I/metabolism , Plasmodium berghei/drug effects , Plasmodium berghei/growth & development , Plasmodium berghei/pathogenicity , Survival Analysis , Treatment Outcome , Vasoconstriction/drug effects
7.
PLoS Pathog ; 9(6): e1003444, 2013.
Article in English | MEDLINE | ID: mdl-23818850

ABSTRACT

Cerebrovascular dysfunction plays a key role in the pathogenesis of cerebral malaria. In experimental cerebral malaria (ECM) induced by Plasmodium berghei ANKA, cerebrovascular dysfunction characterized by vascular constriction, occlusion and damage results in impaired perfusion and reduced cerebral blood flow and oxygenation, and has been linked to low nitric oxide (NO) bioavailability. Here, we directly assessed cerebrovascular function in ECM using a novel cranial window method for intravital microscopy of the pial microcirculation and probed the role of NOS isoforms and phosphorylation patterns in the impaired vascular responses. We show that pial arteriolar responses to endothelial NOS (eNOS) and neuronal NOS (nNOS) agonists (Acetylcholine (ACh) and N-Methyl-D-Aspartate (NMDA)) were blunted in mice with ECM, and could be partially recovered by exogenous supplementation of tetrahydrobiopterin (BH4). Pial arterioles in non-ECM mice infected by Plasmodium berghei NK65 remained relatively responsive to the agonists and were not significantly affected by BH4 treatment. These findings, together with the observed blunting of NO production upon stimulation by the agonists, decrease in total NOS activity, augmentation of lipid peroxidation levels, upregulation of eNOS protein expression, and increase in eNOS and nNOS monomerization in the brain during ECM development strongly indicate a state of eNOS/nNOS uncoupling likely mediated by oxidative stress. Furthermore, the downregulation of Serine 1176 (S1176) phosphorylation of eNOS, which correlated with a decrease in cerebrovascular wall shear stress, implicates hemorheological disturbances in eNOS dysfunction in ECM. Finally, pial arterioles responded to superfusion with the NO donor, S-Nitroso-L-glutathione (GSNO), but with decreased intensity, indicating that not only NO production but also signaling is perturbed during ECM. Therefore, the pathological impairment of eNOS and nNOS functions contribute importantly to cerebrovascular dysfunction in ECM and the recovery of intrinsic functionality of NOS to increase NO bioavailability and restore vascular health represents a target for ECM treatment.


Subject(s)
Cerebrovascular Circulation , Malaria, Cerebral , Microcirculation , Nitric Oxide/metabolism , Plasmodium berghei/metabolism , Acetylcholine/pharmacology , Animals , Biopterins/analogs & derivatives , Biopterins/pharmacology , Cholinergic Agonists , Excitatory Amino Acid Agonists/pharmacology , Female , Malaria, Cerebral/metabolism , Malaria, Cerebral/parasitology , Malaria, Cerebral/physiopathology , Mice , N-Methylaspartate/pharmacology , Nitric Oxide Synthase Type I/metabolism , Nitric Oxide Synthase Type III/metabolism
8.
Malar J ; 12: 138, 2013 Apr 24.
Article in English | MEDLINE | ID: mdl-23617605

ABSTRACT

BACKGROUND: Human cerebral malaria (HCM) is a life-threatening complication caused by Plasmodium falciparum infection that continues to be a major global health problem despite optimal anti-malarial treatment. In the experimental model of cerebral malaria (ECM) by Plasmodium berghei ANKA, bolus administration of nimodipine at high doses together with artemether, increases survival of mice with ECM. However, the dose and administration route used is associated with cardiovascular side effects such as hypotension and bradycardia in humans and mice, which could preclude its potential use as adjunctive treatment in HCM. METHODS: In the present study, alternative delivery systems for nimodipine during late-stage ECM in association with artesunate were searched to define optimal protocols to achieve maximum efficacy in increasing survival in rescue therapy while causing the least cardiac side effects. The baseline electrocardiogram (ECG) and arterial pressure characteristics of uninfected control animals and of mice with ECM and its response upon rescue treatment with artesunate associated or not with nimodipine is also analysed. RESULTS: Nimodipine, given at 0.5 mg/kg/day via a slow and continuous delivery system by osmotic pumps, increases survival of mice with ECM when used as adjunctive treatment to artesunate. Mice with ECM showed hypotension and ECG changes, including bradycardia and increases in PR, QRS, QTc and ST interval duration. ECM mice also show increased QTc dispersion, heart rate variability (HRV), RMSSD, low frequency (LF) and high frequency (HF) bands of the power spectrum. Both sympathetic and parasympathetic inputs to the heart were increased, but there was a predominance of sympathetic tone as demonstrated by an increased LF/HF ratio. Nimodipine potentiated bradycardia when given by bolus injection, but not when via osmotic pumps. In addition, nimodipine shortened PR duration and improved HRV, RMSSD, LF and HF powers in mice with ECM. In addition, nimodipine did not increased hypotension or decreased the speed of arterial pressure recovery when used in rescue therapy with artesunate. CONCLUSIONS: These data show that slow and continuous delivery of lower doses of nimodipine improves survival of mice with ECM in rescue therapy with artesunate while showing a safer profile in terms of cardiovascular effects.


Subject(s)
Antihypertensive Agents/administration & dosage , Malaria, Cerebral/drug therapy , Nimodipine/administration & dosage , Plasmodium berghei/drug effects , Salvage Therapy/methods , Administration, Intravenous , Animals , Antimalarials/administration & dosage , Artemisinins/administration & dosage , Artesunate , Disease Models, Animal , Electrocardiography , Female , Malaria, Cerebral/parasitology , Mice , Mice, Inbred C57BL , Survival Analysis , Treatment Outcome
9.
J Parasitol Res ; 2012: 413052, 2012.
Article in English | MEDLINE | ID: mdl-22496958

ABSTRACT

Macrophage migration inhibitory factor (MIF) is a cytokine that plays a central role in immune and inflammatory responses. In the present paper, we discussed the participation of MIF in the immune response to protozoan parasite infections. As a general trend, MIF participates in the control of parasite burden at the expense of promoting tissue damage due to increased inflammation.

10.
J Neuroimmune Pharmacol ; 7(2): 477-87, 2012 Jun.
Article in English | MEDLINE | ID: mdl-22391863

ABSTRACT

Administration of the exogenous nitric oxide (NO) donor dipropylenetriamine-NONOate (DPTA-NO) to mice during Plasmodium berghei ANKA (PbA) infection largely prevents development of experimental cerebral malaria (ECM). However, a high dose (1 mg/mouse twice a day) is necessary and causes potent side effects such as marked hypotension. In the present study we evaluated whether an alternative, physiologically relevant NO donor, S-nitrosoglutathione (GSNO), was able to prevent ECM at lower doses with minimal side effects. Prophylactic treatment with high (3.5 mg), intermediate (0.35 mg) or low (0.035 mg) doses of GSNO decreased incidence of ECM in PbA-infected mice, decreasing also edema, leukocyte accumulation and hemorrhage incidence in the brain. The high dose inhibited parasite growth and also induced transient hypotension. Low and intermediate doses had no or only mild effects on parasitemia, blood pressure, and heart rate compared to saline-treated mice. PbA infection decreased brain total and reduced (GSH) glutathione levels. Brain levels of oxidized (GSSG) glutathione and the GSH/GSSG ratio were positively correlated with temperature and motor behavior. Low and intermediate doses of GSNO failed to restore the depleted brain total glutathione and GSH levels, suggesting that ECM prevention by GSNO was probably related to other effects such as inhibition of inflammation and vascular protection. These results indicate that ECM is associated with depletion of the brain glutathione pool and that GSNO is able to prevent ECM development in a wide range of doses, decreasing brain inflammation and inducing milder cardiovascular side effects.


Subject(s)
Brain/drug effects , Malaria, Cerebral/prevention & control , Nitric Oxide Donors/pharmacology , S-Nitrosoglutathione/pharmacology , Animals , Blood Pressure/drug effects , Brain/metabolism , Brain/pathology , Disease Models, Animal , Glutathione/analysis , Heart Rate/drug effects , Malaria, Cerebral/pathology , Mice , Mice, Inbred C57BL , Plasmodium berghei
11.
PLoS One ; 7(2): e32048, 2012.
Article in English | MEDLINE | ID: mdl-22348145

ABSTRACT

BACKGROUND: Low nitric oxide (NO) bioavailability plays a role in the pathogenesis of human as well as of experimental cerebral malaria (ECM) caused by Plasmodium berghei ANKA (PbA). ECM is partially prevented by administration of the NO-donor dipropylenetriamine NONOate (DPTA-NO) at high concentration (1 mg/mouse), which also induces major side effects such as a sharp drop in blood pressure. We asked whether alternative strategies to improve NO bioavailability with minor side effects would also be effective in preventing ECM. METHODOLOGY/PRINCIPAL FINDINGS: Mice were infected with PbA and prophylactically treated twice a day with bolus injections of L-arginine, Nω-hydroxy-nor-Arginine (nor-NOHA), tetrahydrobiopterin (BH4), separately or combined, sodium nitrite, sildenafil or sildenafil plus DPTA-NO starting on day 0 of infection. L-arginine and BH4 supplementation, with or without arginase inhibition by nor-NOHA, increased plasma nitrite levels but failed to protect against ECM development. Accordingly, prophylactic treatment with continuous delivery of L-arginine using osmotic pumps also did not improve survival. Similar outcomes were observed with sodium nitrite sildenafil (aimed at inhibiting phosphodiesterase-5) or with DPTA-NO. However, sildenafil (0.1 mg/mouse) in combination with a lower dose (0.1 mg/mouse) of DPTA-NO decreased ECM incidence (82 ± 7.4% mortality in the saline group and 38 ± 10.6% in the treated group; p<0.05). The combined prophylactic therapy did not aggravate anemia, had delayed effects in systolic, diastolic and mean arterial blood pressure and induced lower effects in pulse pressure when compared to DPTA-NO 1 mg/mouse. CONCLUSIONS/SIGNIFICANCE: These data show that sildenafil lowers the amount of NO-donor needed to prevent ECM, resulting also in lesser side effects. Prophylactic L-arginine when given in bolus or continuous delivery and bolus BH4 supplementation, with or without arginase inhibition, were able to increase NO bioavailability in PbA-infected mice but failed to decrease ECM incidence in the doses and protocol used.


Subject(s)
Malaria, Cerebral/prevention & control , Nitric Oxide Donors/therapeutic use , Plasmodium berghei , Animals , Arginine/administration & dosage , Arginine/pharmacology , Arginine/therapeutic use , Chemoprevention/methods , Drug Therapy, Combination , Malaria, Cerebral/parasitology , Mice , Nitric Oxide , Nitric Oxide Donors/adverse effects , Piperazines/administration & dosage , Piperazines/pharmacology , Piperazines/therapeutic use , Purines/administration & dosage , Purines/pharmacology , Purines/therapeutic use , Sildenafil Citrate , Sulfones/administration & dosage , Sulfones/pharmacology , Sulfones/therapeutic use
12.
Eur J Med Chem ; 46(5): 1757-67, 2011 May.
Article in English | MEDLINE | ID: mdl-21396743

ABSTRACT

The synthesis and physico-chemical properties of novel compounds obtained by conjugation of amodiaquine with moieties containing either furoxan or nitrooxy NO-donor substructures are described. The synthesised compounds were tested in vitro against both the chloroquine sensitive, D10 and the chloroquine resistant, W-2 strains of Plasmodium falciparum (P. falciparum). Most of the compounds showed an antiplasmodial activity comparable to that of the parent drug. By comparing the activities of simple related structures devoid of the ability to release NO, it appears that the contribution of NO to the antiplasmodial action in vitro is marginal. All the compounds were able to relax rat aorta strips with a NO-dependent mechanism, thus showing their capacity to release NO in the vessels. A preliminary in vivo study using Plasmodium berghei ANKA-infected mice showed a trend for prolonged survival of mice with cerebral malaria treated with compound 40, which is potent and fast amodiaquine-derived NO-donor, when compared with amodiaquine alone or with compound 31, a milder NO-donor. The two compounds showed in vivo antiplasmodial activity similar to that of amodiaquine.


Subject(s)
Amodiaquine/pharmacology , Antiprotozoal Agents/pharmacology , Malaria, Cerebral/drug therapy , Nitric Oxide Donors/chemistry , Oxadiazoles/chemistry , Plasmodium falciparum/drug effects , Amodiaquine/chemical synthesis , Amodiaquine/chemistry , Animals , Antiprotozoal Agents/chemical synthesis , Antiprotozoal Agents/chemistry , Aorta, Thoracic/drug effects , Aorta, Thoracic/metabolism , Chemistry, Physical , Male , Mice , Mice, Inbred C57BL , Molecular Structure , Parasitic Sensitivity Tests , Plasmodium falciparum/growth & development , Rats , Rats, Wistar , Stereoisomerism , Structure-Activity Relationship
13.
Malar J ; 9: 85, 2010 Mar 24.
Article in English | MEDLINE | ID: mdl-20334682

ABSTRACT

BACKGROUND: Plasmodium berghei ANKA infection in C57Bl/6 mice induces cerebral malaria (CM), which reproduces, to a large extent, the pathological features of human CM. However, experimental CM incidence is variable (50-100%) and the period of incidence may present a range as wide as 6-12 days post-infection. The poor predictability of which and when infected mice will develop CM can make it difficult to determine the causal relationship of early pathological changes and outcome. With the purpose of contributing to solving these problems, algorithms for CM prediction were built. METHODS: Seventy-eight P. berghei-infected mice were daily evaluated using the primary SHIRPA protocol. Mice were classified as CM+ or CM- according to development of neurological signs on days 6-12 post-infection. Logistic regression was used to build predictive models for CM based on the results of SHIRPA tests and parasitaemia. RESULTS: The overall CM incidence was 54% occurring on days 6-10. Some algorithms had a very good performance in predicting CM, with the area under the receiver operator characteristic ((au)ROC) curve > or = 80% and positive predictive values (PV+) > or = 95, and correctly predicted time of death due to CM between 24 and 72 hours before development of the neurological syndrome ((au)ROC = 77-93%; PV+ = 100% using high cut off values). Inclusion of parasitaemia data slightly improved algorithm performance. CONCLUSION: These algorithms work with data from a simple, inexpensive, reproducible and fast protocol. Most importantly, they can predict CM development very early, estimate time of death, and might be a valuable tool for research using CM murine models.


Subject(s)
Algorithms , Behavior, Animal/physiology , Malaria, Cerebral/pathology , Neurologic Examination , Plasmodium berghei/pathogenicity , Animals , Disease Models, Animal , Female , Forecasting , Logistic Models , Mice , Mice, Inbred C57BL , Nervous System Diseases/genetics , Neuropsychological Tests , Plasmodium berghei/parasitology
SELECTION OF CITATIONS
SEARCH DETAIL
...